Samsung Biologics said Wednesday it surpassed 1 trillion won in sales ($768 million) in the first half-year for the first time since its foundation, thanks to the rapid growth of its contract manufacturing organization business.

In the second quarter, the company recorded 651.4 billion in sales and 169.7 billion won in operating profit.

On a consolidated basis, revenue in the first half of this year was 1.62 trillion won with an operating profit of 346.1 billion won. Samsung Biologics' revenue alone in the first six months, after excluding its subsidiary Samsung Bioepis, exceeded 1 trillion won.

Samsung Biologics’ compound annual growth rate (CAGR) in the first half year reached 78.8 percent for three years since 2019.

As a result of the acquisition of Samsung Bioepis (Epis) shares, Samsung Biologics' second-quarter consolidated assets increased to 15.66 trillion won with a capitalization of 8.48 billion won and debt of 7.18 trillion won. However, it remains stable financially with a debt ratio of 84.7 percent and a borrowing ratio of 26.2 percent.

“We are leaping to become a global all-round biopharmaceutical player by adding our R&D capabilities, such as biopharmaceutical development, clinical and research and development capabilities, acquired by merging Epis to our CDMO business,” a Samsung Biologics official said.

The company’s CMO part had 73 backlog orders and 95 CDO (contract development organization) orders in the first half-year.

The company also secured cumulative orders worth $79 billion by signing contracts with multinational majors like Janssen, Merck, GSK, Eli Lilly, Novartis, and others.